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Abstract
Pulmonary hypertension is a well-known complication of systemic sclerosis. 
Patients with systemic sclerosis may develop a pulmonary arteriopathy character-
ized by vascular remodeling, increased pulmonary vascular resistance, and right 
ventricular failure. Pulmonary hypertension may also arise in systemic sclerosis as 
a consequence of interstitial lung disease or left ventricular dysfunction. Vascular 
remodeling is more prevalent than other forms of pulmonary hypertension in sys-
temic sclerosis. The pathogenesis of pulmonary vascular remodeling in this disease 
state is not completely understood; however, there is evidence of a complex process 
involving genetic susceptibility, risk factors, vascular injury, and endothelial 
dysfunction. In those patients with pulmonary arterial hypertension, survival prog-
nosis is extremely poor if the diagnosis is delayed or goes undetected and untreated. 
In recent years, a number of disease-targeted therapies have been developed that 
improve functional capacity, hemodynamics, and survival. Early detection and 
treatment with one or more targeted therapies are essential to improving survival 
when systemic sclerosis is complicated by pulmonary arterial hypertension.
Keywords: pulmonary arterial hypertension, systemic sclerosis, endothelin,  
nitric oxide, prostacyclin
1. Introduction
Systemic sclerosis (SSc) is a multisystem, autoimmune disease characterized 
by excessive collagen deposition and fibrosis of the skin and internal organs. The 
autoimmune process may affect the lungs with the development of interstitial 
fibrosis, pulmonary hypertension, or both. Pulmonary hypertension (PH) may 
result from a pathologic process of remodeling in the pulmonary arteries, in which 
case it is referred to as pulmonary arterial hypertension (PAH). Pulmonary hyper-
tension may also arise secondary to interstitial fibrosis with chronic hypoxemia 
or myocardial fibrosis with postcapillary pulmonary hypertension. Pulmonary 
arterial hypertension associated with systemic sclerosis (SSc-PAH) represents the 
second most common cause of PAH after the idiopathic form of the disease (iPAH). 
Pulmonary arterial hypertension is associated with a progressive rise in pulmonary 
vascular resistance that can result in right ventricular failure and death. Patients 
with SSc-PAH have higher mortality than the idiopathic form of PAH or PAH 
associated with other diseases, such as congenital heart disease. While there is a 
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reasonable amount of information available pertaining to SSc-PAH, much of what 
we know about PAH in general comes from investigations of the idiopathic form of 
the disease. The current chapter will review current knowledge about PAH in the 
patient with systemic sclerosis and contrast it with information that distinguishes 
SSc-PAH from the idiopathic form of PAH.
2. Epidemiology
The prevalence of systemic sclerosis-associated PAH is reported to be between 
5 and 15% of patients with systemic sclerosis [1–3]. There is wide variability in 
reported prevalence rates which range from as low as 3.7% [4] to as high as 43% 
[5]. This variability is in large part due to methods used to establish the diagnosis of 
pulmonary hypertension. While some prevalence studies base reported findings on 
echocardiography, others confirm diagnosis with right heart catheterization. Right 
heart catheterization (RHC) is the gold standard for accurate diagnosis of pulmo-
nary hypertension and for distinguishing pulmonary arterial from postcapillary 
hypertension. Prevalence rates are consistently lower when diagnosis is determined 
by right heart catheterization [6]. In a meta-analysis, Yang et al. found 12 studies 
reporting the prevalence of PAH in SSc ranging from 3.6 to 32% with a pooled 
prevalence of 13%. Five of the 12 studies confirmed the diagnosis of PAH with 
right heart catheterization yielding a pooled prevalence estimate of 8.2%, while the 
pooled prevalence estimate from seven studies relying on echocardiography was 
18% [7]. Even when pulmonary hypertension is diagnosed by right heart catheter-
ization, some patients in cohort studies may refuse to undergo catheterization, thus 
affecting true prevalence [8].
The prevalence of pulmonary hypertension in systemic sclerosis depends on the 
phenotypic form of systemic sclerosis and the pathophysiologic mechanism behind 
the development of PH. The Australian Scleroderma Cohort Study (ASCS) of 232 
patients identified PH in 10.1% of patients with diffuse scleroderma and in 12.7% 
of those with the limited form of the disease [9]. Prevalence of SSc-PAH consis-
tently exceeds interstitial lung disease-PH (ILD-PH) or postcapillary-PH (PC-PH). 
Evaluation of PH subtypes in the ASCS cohort revealed 83.6% with PAH, 2.2% with 
ILD-PH, and 7.8% with PC-PH. The DETECT study, which was designed to develop 
an algorithm for detection of PAH in SSc, included 145 patients all of whom under-
went right heart catheterization revealing 19% with PAH, 6% with ILD-PH, and 
6% with PC-PH [10]. An Italian cohort of 867 consecutive SSc patients included 69 
patients confirmed to have pulmonary hypertension with point prevalence for PAH 
3.7%, PH secondary to ILD 1.4%, and postcapillary-PH 1.3% [4]. The lower preva-
lence of PH in the Italian cohort study raised speculation that ethnic factors might 
influence the prevalence of PH in SSc.
Prevalence of SSc-PAH appears to depend on other factors, such as dura-
tion of systemic sclerosis, gender, and ethnicity. Observations in the Pulmonary 
Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) 
study suggested patients who were female, Caucasian, or suffering with limited 
cutaneous scleroderma were more likely to have PAH [11]. Additionally, a reduc-
tion in DLCO below 55% predicted was noted in 79% of patients with SSc-PAH 
compared to 55% of patients with SSc alone. Other authors have observed a greater 
chance of developing SSc-PAH in male patients age 47 or older [12], patients with 
SSC more than 10 years [13], and those with DLCO <55% [14]. Iudici suggested that 
systemic sclerosis patients of Italian descent may be less likely to develop pulmonary 
hypertension based on observations that prevalence rates were substantially lower 
than those reported in Anglo-Saxon patients [4].
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3. Pathophysiology
3.1 WHO classification of pulmonary hypertensive diseases
The World Health Organization (WHO) has classified pulmonary hypertension 
into five distinct groups on the basis of the primary pathophysiologic mechanism 
leading to elevated pulmonary artery pressure (Table 1) [15]. In a generic sense, 
pulmonary hypertension is diagnosed when mean pulmonary artery pressure 
(mPAP) ≥ 25 mmHg is measured by pulmonary artery catheterization. Patients 
classified as WHO Group 1 develop an arteriopathy of the small precapillary 
pulmonary arteries characterized by endothelial proliferation, smooth muscle layer 
hypertrophy, in situ thrombosis, and formation of plexiform lesions (Figure 1). 
Pulmonary arterial hypertension is defined more specifically as a mPAP ≥25 mmHg 
and also a capillary wedge pressure (CWP) ≤ 15 mmHg and pulmonary vascular 
resistance (PVR) > 3 Wood units (WU) [16]. Those in WHO Group 2 have elevated 
pulmonary artery pressure with a postcapillary origin typically related to left heart 
disease or dysfunction. WHO Group 3 pulmonary hypertension is a consequence 
of chronic hypoxia and attendant vasoconstriction as seen in chronic lung diseases, 
such as pulmonary fibrosis or emphysema. The fourth WHO Group constitutes 
those with pulmonary vascular obstruction, most often due to chronic thromboem-
bolic disease. Finally, WHO Group 5 is a group of patients with pulmonary hyper-
tension of mixed etiologies that do not fit within the other categories.
3.2 Histopathology
Patients who develop the characteristic vasculopathy of WHO Group 1 PAH 
experience a progressive rise in pulmonary vascular resistance resulting from the 
gradual occlusion of smaller vessels by cellular hyperproliferation, thrombosis, and 
plexiform lesion formation that obstruct blood flow. The resulting rise in resistance 
to blood flow through the pulmonary circulation causes right ventricular strain with 
initial compensation and hypertrophy. Eventually the rising resistance overwhelms 
the right ventricle resulting in its failure.
Pulmonary hypertension as it occurs in the scleroderma spectrum of diseases 
can develop by virtue of one or more mechanisms and can be classified as WHO 
Group 1 with the characteristic features of a precapillary arteriopathy, as WHO 
Group 2 when scleroderma affects myocardial physiology, or as WHO Group 3 if 
the patient primarily suffers from interstitial fibrosis and hypoxemia. Patients with 
systemic sclerosis may have complex forms of pulmonary hypertension involving 
more than one of these mechanisms. Treatment is dependent on the mechanism 
or mechanisms behind rising pulmonary vascular resistance, so it is important to 
carefully establish the root cause, or causes, for pulmonary hypertension in this 
patient population. Pulmonary arterial hypertension is the most common form of 
pulmonary hypertension to affect patients with systemic sclerosis. Therefore, this 
chapter’s focus is primarily on the pathogenesis of pulmonary arterial hyperten-
sion. While other mechanisms leading to pulmonary hypertension in this group 
will be reviewed, the development of SSc-PAH is a devastating complication, and 
the greatest body of information available pertains to the WHO Group 1 type of 
arteriopathy.
Characteristic histopathologic features of pulmonary vascular remodeling 
observed in the patient with WHO Group 1 PAH are well-described and involve all 
layers of the pulmonary arterial vessels (Figure 1A) [17, 19, 21]. It is not uncom-
mon for a similar process to affect the postcapillary venules in systemic sclerosis. 
A majority of patients will have in situ vessel thrombosis [18]. Flow-limiting 
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pathologic features involving the intimal layer of the pulmonary arteries include 
eccentric or concentric intimal thickening and formation of plexiform or angio-
matoid lesions (Figure 1B) [17, 19, 21]. There is excessive cell proliferation and 
Table 1. 
The World Health Organization classification of pulmonary hypertensive diseases.
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hypertrophy of the smooth muscle layer. Thickening of the adventitial layer, 
primarily due to collagen deposition, is also noted in these patients [17, 19–21].
Areas of eccentric intimal thickening may represent fibrotic organization of 
localized thrombi. This concept is supported by observations of myofibroblast 
infiltration and accumulation of mucopolysaccharides in these localized lesions 
along the vessel lumen [17]. Eccentric intimal lesions of this nature have been 
demonstrated in lung explants from patients with severe idiopathic PAH and those 
with the CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclero-
dactyly, and telangiectasias) variant of scleroderma [22]. Vascular resistance is also 
increased by concentric proliferation of the endothelial cell layer creating the well-
described “onion skin” lesion that is thought to involve myofibroblasts and smooth 
muscle cells (SMC), as well as endothelial cells [23, 24]. Plexiform lesions consist of 
complex vascular networks with a myofibroblast core which distorts the vessel wall 
as it expands and extends into the lumen and the connective tissues surrounding 
the vessel [23]. A rosary of dilated channels may form an angiomatoid, or dilation, 
lesion and obstruct arterial flow [25]. Although specific mechanisms involved in 
intimal remodeling are yet to be defined with clarity, it is largely believed that the 
processes begin with endothelial injury and, in genetically susceptible individuals, 
result in endothelial proliferation, smooth muscle cell and myofibroblast migration, 
decreased apoptosis, and deposition of extracellular matrix [17, 18, 26].
Normally, the medial layer of muscularized arteries accounts for about 10–15% 
of the outer arterial diameter, while in iPAH, it may be 30–60% of the outside 
diameter [20, 27]. Thickening of the medial layer is largely due to cell hypertrophy; 
however, hyperplasia of the smooth muscle cells and accumulation of extracel-
lular matrix also contribute to the shift in tunica media dimension [17, 28]. Non-
muscularized arteries may become muscularized with peripheral extension of 
proximal smooth muscle cell segments and pericyte differentiation into smooth 
muscle cells [19].
The adventitial layer is comprised of fibroblasts and extracellular matrix (ECM) 
components. While it accounts for roughly 15% of vessel diameter under normal 
circumstances, it may represent double that in the patient with PAH [17]. In addition 
to its role in providing structural support for the vessel, there is evidence that inflam-
matory cells and extracellular matrix components of the adventitia may serve a role 
in the regulation of cell activities in other layers [29]. Typical components of the 
pulmonary vascular ECM include elastin, collagens, fibronectin, tenascin, throm-
bospondin, growth factors, and matrix metalloproteinases and proteoglycans [30]. 
Normal vessel structural and functional integrity depend on a balance between ECM 
Figure 1. 
Histopathology of vascular remodeling in pulmonary arterial hypertension. (A) Medial hypertrophy and 
cellular intimal thickening. (B) Fibrin thrombi in glomoid plexiform lesion. Reprinted by permission from 
Springer Nature: Ishibashi-Ueda and Ohta-Ogo [21]. Copyright 2017.
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deposition and degradation. Turnover is regulated by matrix metalloproteinases, 
adamalysins, serine elastase, and endogenous enzyme inhibitors [31]. In PAH exces-
sive deposition of ECM contributes to vascular remodeling and decreased vessel wall 
compliance. Examination of the pulmonary vascular ECM in iPAH reveals promi-
nent deposition of collagens I and III, enhanced collagen metabolism, alterations in 
proteoglycans and elastin, upregulation of tenascin C which is involved in intimal 
hyperplasia, and modification of fibronectin contributing to SMC proliferation 
and migration [32–35]. Scleroderma is a disease characterized by overproduction of 
ECM, although there have been no studies detailing ECM composition in SSc-PAH.
Studies comparing the pathologic features of iPAH to those with connective 
tissue disease- associated PAH (CTD-PAH), and specifically SSc-PAH, have high-
lighted both similarities and differences between the groups. In a study of lung 
explants from transplant recipients, Stacher et al. compared the features of vascular 
remodeling in patients with iPAH and CTD-PAH [36]. The investigators noted more 
pronounced morphologic changes in the smaller-sized and precapillary arteries 
in CTD-PAH. Plexiform lesions were noted with similar frequency but had a more 
scattered distribution in the patients with connective tissue disease. Histopathologic 
studies comparing these patient groups also reveal more active interstitial inflam-
mation and fibrosis in systemic sclerosis and other connective tissue diseases [19, 
36, 37]. In a study comparing tissue from 24 patients with SSc-PAH and 9 iPAH 
patients, Argula et al. noted fewer plexiform lesions and more interstitial cellularity 
and fibrosis in the SSc-PAH group, while there was little difference in intimal pro-
liferation or arteriolar smooth muscle hypertrophy [37]. In contrast, Overbeek and 
colleagues found no plexiform lesions in a group of patients with limited cutaneous 
systemic sclerosis and PAH, while these lesions were present in 10 of 11 comparative 
iPAH patients [38]. Further intimal fibrosis and fibrosis of the pulmonary veins and 
venules were observed with significantly higher frequency in SSc-PAH. While there 
are similarities in the overall pattern of vascular remodeling in iPAH and SSc-PAH, 
differences are notable and suggest distinct pathogenetic mechanisms may be in 
play. Additionally, inflammation and fibrosis may have a greater role in SSc-PAH.
3.3 Pathogenesis
The coordinated mechanisms leading to vascular remodeling in PAH have been 
the subject of intensive investigation in recent years. It has been 18 years since Gaine 
proposed a theoretical model of the pathogenesis of PAH [18]. This model continues 
to serve as a basis for our basic understanding of the pathobiology of the disease 
and has been a platform for the development of approved therapies for WHO 
Group 1 PAH in use today. The model suggests a convergence of factors including 
genetic susceptibility, exposure to risk factors, vascular injury, and endothelial 
dysfunction leading to progressive remodeling of vasculature and rising pulmonary 
vascular resistance.
3.3.1 Genetic mutations
Evidence of a genetic basis for PAH was first reported in 2000 with the discovery 
of the bone morphogenetic protein receptor II (BMPR2) gene mutation in patients 
with heritable PAH [39, 40]. Mutation of this gene has been identified in at least 
70–80% of cases of heritable PAH and 15–25% of sporadic iPAH [41]. BMPR2 
protein concentrations are decreased by 75% in lung tissue and endothelial cells 
from subjects with PAH [24]. Other gene mutations related to BMPR2 and its down-
stream signaling pathway are now known including mutations in ALK1, ENG, and 
genes encoding components of the SMAD downstream signaling pathway [19, 41]. 
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Mutations unrelated to the BMPR2 signaling pathway have also been identified in a 
very small percentage of PAH patients and include KCNK3, which encodes a pH-sen-
sitive potassium channel, and CAV1, which encodes a membrane protein, caveolin 
1, which is essential for the formation of lipid rafts or caveolae [41]. While no link 
between the development of SSc-PAH and mutation of BMPR2 has been established, 
other unique mutations have been identified in the systemic sclerosis population 
with PAH. For instance, a rare functional polymorphism in the TLR2 gene, which 
promotes induction of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-
alpha), is associated with the development of PAH in systemic sclerosis [42]. The 
development of diffuse cutaneous scleroderma, fibrosing alveolitis, and PAH has 
been linked to polymorphisms in TNFAIP3, which regulates the NF-kB inflamma-
tory pathway [43]. Genetic variation in the promoter region of UPAR, the urokinase-
type plasminogen activator receptor, has been associated with digital ulceration and 
PAH in scleroderma patients [44]. Clearly, there is evidence for genetic susceptibility 
to develop PAH in systemic sclerosis, although genetic mechanisms appear to differ 
from those associated with iPAH.
BMPR2 is a member of the transforming growth factor-beta (TGF-beta) super-
family of genes and normally functions to limit proliferation of smooth muscle cells 
and enhance endothelial cell survival by inhibiting apoptosis [45]. In contrast, TGF-
beta is thought to promote SMC proliferation, matrix deposition, and alterations 
in endothelial cell growth [46, 47]. TGF-beta is known for fibrotic effects in several 
disease states, among which are systemic sclerosis [48]. Evidence from investiga-
tions of heritable PAH and preclinical models of SSc suggests that endothelial injury 
and consequent pulmonary vasculopathy may arise from an imbalance in TGF-beta/
BMP signaling pathways [49–53]. For example, reduced BMPR2 receptor expression 
in heritable PAH correlates with increased activity of TGF-beta and its downstream 
signaling pathways. Reduction in BMPR2 levels in patients with systemic sclerosis 
also correlates with enhanced activity of TGF-beta and downstream SMAD2 
and MAPK signaling pathways. Based on these observations, a theory has been 
advanced that heightened TGF-beta activity in systemic sclerosis might suppress 
BMP signaling pathways that serve to protect the endothelium [19].
In addition to the disruption created by structural remodeling in the pulmonary 
vessels, endothelial injury and dysfunction may lead to imbalances in production of 
mediators that affect vascular tone and platelet aggregation and further regulate cell 
proliferation. Immunochemical studies have demonstrated reduced levels of nitric 
oxide synthase and prostacyclin synthase in the pulmonary vascular endothelium 
[54, 55]. These enzymes are critical to the endogenous production of nitric oxide 
and prostacyclin, both of which have vasodilatory and antiproliferative effects. 
The production of thromboxane is increased leading to enhanced vasoconstric-
tion and in situ thrombosis [56]. Vasoconstriction and cell proliferation are pro-
moted by increased production of endothelin-1 by pulmonary endothelium [57]. 
Endothelin-1, survivin, and vascular endothelial growth factor (VEGF) have been 
found in plexiform lesions and may augment endothelial and smooth muscle cell 
proliferation while limiting cell apoptosis [57–59]. Levels of nitric oxide synthase, 
prostacyclin synthase, and tumor suppressors, such as caveolin-1, are reduced in the 
plexiform lesions [54, 55, 60]. The imbalances in production of vasoactive media-
tors have largely driven the development of treatments designed to counteract these 
imbalances and improve pulmonary vascular resistance.
3.3.2 Serotonin
The role of serotonin in the pathogenesis of PAH has been a topic of interest and 
investigation for several years. Serotonin is thought to promote vasoconstriction 
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and remodeling of pulmonary vessels by stimulating proliferation of SMCs and 
fibroblasts [61–63]. The induction of SMC proliferation may be affected by sero-
tonin transporter activation of the platelet-derived growth factor-beta (PDGF-B) 
receptor [64]. In SSc patients, serotonin has been shown to induce ECM production 
by interstitial fibroblasts in a TGF-beta-dependent manner [65]. When a group 
of SSc-PAH patients were treated with ketanserin, a selective antagonist of S2 
serotonergic receptors, a majority experienced reductions in pulmonary vascular 
resistance [66]. The serotonin pathway may hold promise for the development of 
new treatment approaches to SSc-PAH in the future.
3.3.3 Epigenetics
Epigenetic mechanisms affecting changes in cellular function in PAH have been 
a focus of more recent research. Epigenetic processes alter gene expression without 
effecting changes in DNA sequence. Epigenetic mechanisms may involve DNA 
methylation, modification of histone proteins, or RNA interference via microRNAs 
[67]. Extensive methylation of cytosine residues in the CpG dinucleotide sequences 
of the BMPR2 gene promoter region suppresses BMPR2 gene expression in SSc-
PAH [68]. Elevated histone deacetylase levels have been noted in the lungs of PAH 
patients, and the inhibition of the deacetylase reduces proliferation of vascular 
fibroblasts and PDGF-stimulated SMC growth [69]. A number of microRNAs have 
been identified that influence cellular functions in hereditary and iPAH [19]. For 
instance, miR424 and miR503 normally suppress expression of fibroblast growth 
factor-2 (FGF-2); however, they are decreased in iPAH leading to an upregulation 
of FGF-2 expression [70]. These are just some representative examples of the grow-
ing knowledge of the role of epigenetic factors in PAH.
3.3.4 Cytokines and growth factors
The discovery of gene mutations involving the TGF-beta receptor family focused 
attention on the role of cytokines and growth factors in vascular remodeling of 
PAH. Observations of inflammatory cell infiltrates associated with vascular lesions 
and the presence of elevated cytokine levels in PAH have further supported a role 
for inflammation in this disease process. Lymphocytes, macrophages, dendritic 
cells, and mast cells have all been demonstrated on histopathologic examination 
of immune cell infiltrates in vascular lesions [17, 71, 72]. Elevated levels of several 
cytokines have been reported in iPAH including IL-1beta, IL-2, IL-4, IL-6, IL-8, 
IL-10, and IL-12p70, TNF-alpha, and chemokines CXC3L1, CCL2, and CCL5 
[73–77]. The exact role of inflammation in the pathogenesis of PAH is unclear. 
Inflammation may reflect a consequence of hypoxia associated with PAH, as 
acute and chronic inflammation are known to occur in the setting of hypoxia. 
Alternatively, inflammatory mechanisms may be the drivers behind vascular cell 
injury and dysfunction. Macrophages are known to concentrate within and around 
advanced vascular lesions in iPAH and are thought to play a significant role in 
the remodeling process [78]. IL-6 produced by activated adventitial fibroblasts 
has been shown to induce a macrophage phenotype with proinflammatory and 
profibrotic characteristics [79]. Speculation about the role of immune dysregula-
tion is supported by an observed deficiency of regulatory T cells in the lungs from 
iPAH patients [80]. In contrast to a deficiency of T-cell subpopulations, circulat-
ing autoantibodies and ectopic expansion of pulmonary lymphoid tissue in PAH 
patients suggest there is excessive B-cell activation [81]. PDGF has been implicated 
in the pathogenesis of PAH. Although originally discovered as a product of plate-
lets, isoforms of this growth factor are also known to be secreted by macrophages, 
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endothelial cells, SMCs, and fibroblasts [82]. PDGF is a potent mitogen and 
chemoattractant for endothelial cells, smooth muscle cells, and fibroblasts. PDGF 
receptor-beta expression is more intense in small and postcapillary vessels in 
SSc-PAH than iPAH [83]. The PDGF receptor antagonist, imatinib, was investi-
gated for treatment of PAH, and during the initial study phase, improvements in 
hemodynamics and exercise capacity were noted. However, the long-term extension 
study was terminated early due to severe and unexpected adverse events including 
intracranial hemorrhage, death, and other side effects [84].
3.3.5 Autoantibodies
Autoantibodies against endothelial cell antigens may promote pulmonary vascu-
lar remodeling, especially in SSc-PAH. The expression of anti-endothelial cell anti-
bodies and target antigens has been confirmed in iPAH and SSc-PAH, although the 
role of these antibodies in the pathogenesis of PAH remains undetermined [85, 86]. 
Anti-endothelial cell antibody levels in serum of connective tissue disease patients 
with or without PAH were evaluated by Li and colleagues compared with control 
subjects [87]. While endothelial cell antibodies were detected at similar levels in 
connective tissue disease patients irrespective of whether PAH was present, one 
specific endothelial antibody subtype (anti-22kD) was only found in the patients 
with PAH. A second subtype (anti-75kD) was noted at significantly higher levels in 
patients with PAH. The investigators concluded that these subtypes of endothelial 
antibody might indicate a more specific risk for PAH in connective tissue diseases. 
Tamby also demonstrated the presence of serum immunoglobulin anti-fibroblast 
antibodies in patients with iPAH and SSc-PAH with distinct reactivity against target 
antigens [88]. While these observations imply immunosuppressive therapy should 
be a treatment option for SSc-PAH and possibly iPAH, there is no evidence to date 
that this approach is beneficial. A prospective, multicenter trial to evaluate the effect 
of rituximab on disease progression in subjects with SSc-PAH receiving concurrent 
standard medical therapy is currently ongoing.
3.3.6 Cancer similarities
Certain features of pulmonary vascular cell dysfunction in patients with PAH 
have led to the suggestion that vascular remodeling may represent a cancer-like 
process involving the cellular constituents of the pulmonary arteries. Investigators 
have reported evidence of proliferative, apoptosis-resistant, cancer-like behav-
ior in endothelial cells, SMCs, and fibroblasts from subjects with PAH [89–91]. 
Specific observations leading to this concept include monoclonal expansion of 
endothelial cells from patients with iPAH when compared to patients with PAH 
associated with congenital heart disease, instability of short DNA microsatellite 
sequences within plexiform lesions, somatic chromosome abnormalities in the 
lungs of patients with PAH, persistent hyperproliferative and apoptosis-resistant 
state when endothelial cells are removed from their in vivo environment, and 
altered energy metabolism [92]. Enhanced proliferation of pulmonary vascular 
cells may be a consequence of excessive growth factor release from the ECM, 
alterations in growth factor production or receptor expression, and/or alterations 
in intracellular mitogenic signals [93–95]. Abnormal increases in key apoptotic 
factors including Bcl-xL, Bcl-2, and survivin have been reported in pulmonary 
vascular cells from PAH patients [58, 96, 97]. Although there is evidence of 
enhanced cell proliferation and resistance to apoptosis, vascular remodeling in 
PAH is distinguished from cancer in that there is no evidence that pulmonary 
vascular cells have the ability to reproduce in a clonal fashion without control.
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Table 2. 
Summary of factors involved in pathogenesis of pulmonary arterial hypertension.
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Endothelial cells, SMCs, and adventitial fibroblasts from patients with PAH are 
not only more proliferative and apoptosis-resistant but rely more on glycolysis for 
energy production [89, 98–100]. Mitochondria demonstrate a metabolic shift from 
glucose oxidation to uncoupled aerobic glycolysis similar to that described in cancer 
cells [101]. The glycolytic pathway increases NADPH production which in turn 
enhances antioxidant defenses while producing ribonucleotides for DNA synthesis. 
This shift in metabolism serves as a mechanism to support rapid cell proliferation.
3.3.7 Ion channels
Increased cytosolic calcium levels in SMCs of patients with PAH promote not 
only contraction but also hyperproliferation and apoptosis resistance [41]. Elevated 
cytosolic Ca+2 levels in PAH have been linked to downregulation of voltage-gated 
potassium channels, such as Kv1.5 [102]. Downregulation or dysfunction of voltage-
gated potassium channels allows membrane depolarization and influx of calcium. 
Cytosolic calcium levels are further enhanced by impaired mitochondrial Ca+2 
uptake. The resulting increases in intracellular calcium drive cells into the cell cycle, 
thus enhancing proliferation [103].
Research has certainly revealed that the pathogenesis of PAH is a very complex 
process, and our understanding of the mechanisms involved is far from complete. 
Knowledge of imbalances in endogenously produced vasomotor regulators has allowed 
the development of therapies that have improved quality of life and survival. However, 
it is apparent that PAH is not merely a disease of vasomotor dysfunction, but one 
that involves complex genetic mechanisms, cytokines, inflammation, and metabolic 
derangements (Table 2). While the progressive arteriopathy of iPAH and SSc-PAH 
shares many features, research has disclosed distinct differences in the pathogenesis of 
the two entities that may lead to more effective treatments for each in the future.
4. Screening and diagnosis
The majority of patients with SSc-PAH are diagnosed with PAH when the 
pulmonary arteriopathy is well established, while a small percentage is diagnosed at 
an early, asymptomatic stage [2]. Even when symptoms are present, the symptoms 
of PAH are nonspecific and may be attributed to other causes. Mortality is higher in 
patients with SSc-PAH than iPAH or PAH associated with other disease processes, 
such as congenital heart disease [104, 105]. An estimated 1-year survival of 84% 
for patients with iPAH contrasts with a 55% rate of survival at 1 year in SSc-PAH 
[106]. Patients with SSc-PAH have a higher mortality rate than those with non-
scleroderma connective tissue disease-associated PAH [107]. Further, mortality is 
higher in patients with SSc- PAH than in systemic sclerosis patients without lung 
involvement or with lung involvement other than PAH [108]. In recent years, PAH 
and lung fibrosis have replaced scleroderma renal crisis as major causes of death in 
systemic sclerosis [109]. Pulmonary arterial hypertension accounts for about 30% 
of deaths in systemic sclerosis [109, 110]. Three-year survival rates of 70, 50, and 
20% have been reported in treated SSc-PAH patients with WHO FC 1, FC 2, and FC 
3 symptoms, respectively [107]. Earlier discovery of PAH in the systemic sclerosis 
patient may have an impact on these discouraging survival statistics. In a study 
by Humbert et al., the 1-, 3-, 5-, and 8-year survival rates in a cohort of SSc-PAH 
patients managed according to routine practice were 75%, 31%, 25%, and 17%, 
respectively, compared to survival rates of 100%, 81%, 73%, and 64%, respectively, 
in a group managed in a proactive detection program [111]. These data underscore 
the importance of consistently screening patients with systemic sclerosis for PAH.
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Although experts agree on the importance of screening for SSc-PAH in order to 
detect vascular involvement at an earlier stage, there is less consensus on the most 
effective algorithm to confirm the presence of PAH. Several risk factors have been 
identified that signal the potential for the development of SSc-PAH (Table 2). 
Patients who are older and have long-standing SSc are at greater risk of developing 
PAH [1, 112]. The limited cutaneous form of SSc has historically been considered a 
risk for PAH; however the presence of diffuse cutaneous SSc has also been reported 
with similar prevalence [13, 113]. Anticentromere antibodies (ACA), anti-U1-ribo-
nucleoprotein antibodies (RNP), and a nucleolar pattern of antinuclear antibody 
(nucleolar-ANA) are associated with an increased risk of SSc-PAH [114–117]. The 
absence of anti-Scl 70 has been associated with the development of PAH, while the 
presence of these autoantibodies is associated with the development of interstitial 
lung disease [14]. Symptoms that relate to PAH are nonspecific and typically relate 
to progressive right ventricular (RV) dysfunction. Common symptoms include 
shortness of breath, fatigue, weakness, chest pain, and syncope [118]. Physical 
findings suggesting PAH include an accentuated pulmonary component of the 
second heart sound, an RV third heart sound, a pansystolic murmur of tricuspid 
regurgitation, and a diastolic murmur of pulmonary regurgitation [16]. Jugular 
venous distension, hepatomegaly, ascites, edema, and cyanosis are findings in 
advanced disease. Certain findings on electrocardiogram, such as right axis devia-
tion, RV hypertrophy, RV strain, and right bundle branch block, may point to a 
diagnosis of PAH. Electrocardiogram abnormalities are more likely to be found in 
severe PAH. A normal electrocardiogram does not exclude PAH. Plain chest radi-
ography can also be helpful in diagnosing PAH if the X-ray demonstrates central 
pulmonary artery enlargement, pruning of the peripheral vessels, or enlargement 
of right heart chambers. A chest radiograph may be helpful in distinguishing other 
causes of PH if interstitial lung disease or pulmonary venous congestion is present. 
Similarly, pulmonary function tests can be very helpful in detecting airway disease 
or restrictive lung disease that could lead to WHO Group 3 PH. Pulmonary func-
tion testing in patients with SSc-PAH may reveal severe gas diffusion impairment. 
Mukerjee et al. noted that a DLCO <50% was 90% specific but only 39% sensitive 
in excluding a diagnosis of SSc-PAH [6]. A DLCO/VA <70% or FVC percent/DLCO 
percent >1.6 has been considered predictors for the development of SSc-PAH [119]. 
Pulmonary function testing and CXR or high-resolution CT scanning are helpful in 
distinguishing PAH from WHO Group 3 PH associated with ILD. Echocardiography 
has been considered a noninvasive alternative to RHC in determining the presence 
of SSc-PAH, although certain limitations are recognized. Factors affecting image 
quality have been noted to limit the ability to estimate pulmonary artery systolic 
pressure accurately in patients who were later confirmed to have PAH by RHC [120, 
121]. Right heart catheterization is the gold standard for diagnosis of PAH and is 
required to confirm PAH. Right heart catheterization with saline volume challenge 
can be helpful in distinguishing WHO Group 2 PH due to abnormal left ventricular 
function in systemic sclerosis. Several algorithms have been proposed that rely on 
various combinations of symptoms, physical exam findings, biomarkers, PFTs, and 
findings on echocardiography to determine which patients warrant definitive study 
with right heart catheterization [10, 16, 120, 122, 123].
A screening algorithm including assessment of symptoms, Doppler echocar-
diography, and right heart catheterization was studied in a French prospective 
multicenter study by the Itinerair-Scleroderma Investigators Group that enrolled 
599 patients with scleroderma [120]. The study was limited to patients without 
significant pulmonary function abnormalities. Patients with a velocity of tricuspid 
regurgitation (VTR) > 3 m/s regardless of symptoms and patients with a VTR 
2.5–3 m/s with dyspnea were considered at risk for PAH and underwent right heart 
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catheterization (RHC). Right heart catheterization confirmed mild PAH in 18 of 33 
patients suspected of having PAH based on symptoms and/or Doppler echocardiog-
raphy. Twelve of the 33 patients did not have PAH, and 3 patients were confirmed 
to have left heart dysfunction. This algorithm allowed early detection of SSc-PAH; 
however a substantial number of patients undergoing RHC did not have PAH.
An alternative screening algorithm was suggested by the Australian Scleroderma 
Interest Group (ASIG) that employs N-terminal pro-brain natriuretic peptide 
(NT-proBNP) levels and PFT data to predict the presence of PAH [122]. Data to 
develop this algorithm were collected from the Australian Scleroderma Cohort 
Study, a multicenter study of risk and prognostic factors for cardiopulmonary 
outcomes in systemic sclerosis. NT-proBNP levels from SSc patients with confirmed 
PAH were compared with a group at risk for PAH (systolic PAP TTE > 36 mmHg, 
hemoglobin corrected DLCO <50% predicted, and/or FVC/DLCO percent 
predicted ≥1.6), a group with ILD, and a group of controls with no evidence of 
cardiopulmonary complications. NT-proBNP levels were positively correlated with 
systolic PAP by transthoracic echocardiogram, mean PAP by RHC, pulmonary 
vascular resistance, and mean right atrial pressure. The authors proposed a model 
in which patients screened positive when NT-proBNP was ≥209.8 pg./ml and/or 
DLCO was <70.3% with FVC/DLCO ≥1.82. They noted a sensitivity of 100% with 
specificity 77.8% for SSc-PAH but acknowledged a need for prospective validation 
of the model.
A third screening algorithm was employed in the DETECT study, a multina-
tional, cross-sectional investigation of factors in SSc patients that could serve to 
detect PAH at an earlier stage [10]. A broad range of variables (112 in total) pertain-
ing to standard demographic and clinical characteristics, serum tests, electrocar-
diography, and echocardiography were examined in patients with a diagnosis of 
systemic sclerosis for more than 3 years, a predicted DLCO <60%, and a predicted 
FVC ≥ 40%. About 466 patients underwent RHC and 87 (19%) were confirmed to 
have WHO Group 1 PAH. Univariate and multivariate analyses were used to select 
the variables with best discriminatory power for predicting PAH. These variables 
Table 3. 
2015 ESC/ERS recommendations for pulmonary arterial hypertension screening in systemic sclerosis.
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were incorporated in a two-step algorithm. Six non-echocardiographic variables 
were used in Step 1 to recommend echocardiography (FVC % predicted/DLCO % 
predicted, current/past telangiectasias, serum anti-centromere antibody, NT-pro 
BNP, serum urate, ECG with right axis deviation), and a decision to recommend 
RHC in Step 2 was based on right atrial area and velocity of tricuspid regurgitation 
(VTR). Complete Step 1 data were available for 356 patients. About 52 patients did 
not meet Step 1 criteria for referral to echocardiography. Of these, two patients 
(4%) were determined to be false PAH negative. Complete Step 2 data were avail-
able for 267 patients. About 69 patients did not meet Step 2 criteria for referral to 
RHC. Of these, one patient was determined to be false PAH negative. Of the 198 
patients referable for RHC, 69 were true PAH positive. The overall sensitivity of this 
algorithm was 96% with a specificity of 48%, a 62% rate of referral for RHC, and a 
4% false PAH negative rate.
Summary recommendations for PAH screening in systemic sclerosis from the 
2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) 
Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension are sum-
marized in Table 3. The guidelines support a combined approach incorporating 
biomarkers, PFTs, and echocardiography for baseline screening in patients with 
systemic sclerosis. Annual screening with these indicators should be considered 
for all patients with systemic sclerosis. Systemic sclerosis patients with a mean 
PAP from 21 to 24 mmHg should continue to be monitored closely for progression. 
Exercise echocardiography has been used for early detection of PAH in systemic 
sclerosis [124, 125]; however the ESC/ERS do not recommend this approach. A 
summary diagnostic algorithm is provided in Figure 3.
5. Treatment
As understanding of the pathogenesis of PAH has evolved over the past two 
decades, a number of medical therapies have been developed that improve exercise 
capacity, hemodynamics, quality of life, and survival. Treating PAH has become a 
complex exercise now that there are multiple agents that can be employed alone or in 
various combinations. It is important to remember that PAH is a progressive disease 
process, and any treatment plan requires ongoing monitoring and adjustment if 
treatment goals are not being met. Although far fewer patients with PAH require lung 
transplantation in the era of targeted medical therapy, there are those who progress 
even on maximal medical therapy leaving transplantation as their last viable option.
The treatment of pulmonary arterial hypertension involves not only selection of 
appropriate agents for inclusion in a treatment plan but an ongoing process of assess-
ment of patient characteristics that should determine the selection of medications. 
The concept of using a risk assessment tool to aid selection of appropriate agents for 
treatment was introduced in 2006 based on studies showing correlation between 
clinical characteristics of disease and survival [104]. For instance, 6 MW, FC, and 
certain hemodynamic measures were shown to directly correlate with prognosis. 
These findings were used to develop a tool to evaluate a patient’s risk of early death. 
Patients could be categorized as low or high risk of rapid progression to death, and 
treatment agents could be selected based on the level of risk in order to modify the 
course of disease and extend survival. This concept further evolved with the develop-
ment of a risk calculator using data from the American REVEAL Registry [126, 127]. 
The REVEAL Registry was a 3-year longitudinal registry of 2967 WHO Group 1 PAH 
patients with data collected pertaining to the clinical characteristics, evaluation, 
treatment, and outcomes. Data from this registry was used to develop a user-friendly 
algorithm to determine a patient’s risk of demise in the short term. Most recently, 
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the ESC/ERS further refined the characteristics used to assess risk of progression in 
PAH and presented criteria that classified patients as low, moderate, or high risk of 
progression to near-term death (Figure 2). Using the ESC/ERS risk assessment algo-
rithm, patients categorized as low risk have an estimated 1-year mortality <5%. Those 
within the intermediate-risk group have an estimated 1-year mortality of 5–10%, and 
those in the high-risk group have an estimated 1-year mortality >10%.
5.1 Risk assessment
Following the accurate diagnosis of PAH (Figure 3), a careful assessment of 
severity of disease should be completed before deciding on specific treatment 
options. This assessment is critical at the outset of treatment, but it remains an 
important part of ongoing patient management. Given that PAH can progress 
rapidly, even on therapy, it is necessary to complete a reevaluation of severity of ill-
ness and risk stratification periodically several times a year. If patients show signs of 
deterioration in their clinical parameters, treatment plan adjustments are in order.
5.1.1 Functional capacity
Assessment of the severity of illness begins with an understanding of symptoms 
and functional capacity. Patients who present symptoms, such as shortness of 
breath, fatigue, or edema, that have developed and worsened over a short period 
of time are at higher risk of early death. Further, those with overt signs of right 
heart failure, such as edema, ascites, cyanosis, or syncope, are in a high-risk group 
requiring urgent attention. The World Health Organization functional class (FC) 
is a valuable indicator of severity of illness and has been shown to correlate with 
survival [128, 129]. Patients are classified in four groups (FC 1–4) based on degree 
Figure 2. 
ESC/ERS risk assessment in pulmonary arterial hypertension (estimated risk for 1-year mortality).
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of functional impairment (Table 4). Patients who have FC 3 or 4 functional impair-
ment are considered high risk; a goal of any treatment plan is to achieve FC 1 or 2 
functional capacity [16]. Although functional class has been shown to correlate well 
with survival prognosis, it is a subjective measure of symptoms which is subject to 
interpretation by the healthcare provider [130]. Another important indicator of 
illness severity is the 6 min walk (6 MW) test [131]. The 6 MW test is a submaximal 
exercise test that is easy to perform in the outpatient or inpatient setting. The 6 MW 
test has been shown to correlate with survival and has served as a primary endpoint 
in the majority of clinical investigations leading to today’s therapeutic options [132, 
133]. Six-min walk distance has been shown to correlate with pulmonary pres-
sures and represent a direct predictor of mortality in SSc-PAH [131]. The ESC/ERS 
Guidelines suggest that patients who can ambulate >440 m have better survival 
prognosis and are an appropriate goal to target when making treatment decisions 
[16]. The 6 MW test does have limitations with its reliability being challenged 
by factors such as age, gender, weight, comorbid conditions, and the individual’s 
Figure 3. 
Algorithm for the diagnosis of pulmonary arterial hypertension.
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motivation. Cardiopulmonary exercise testing (CPET) is often employed to evalu-
ate exercise capacity in this population. CPET can provide important information 
about general exercise capacity, as well as more detailed information about gas 
exchange, ventilation, and cardiac function during exercise. Patients with PAH will 
demonstrate exercise limitation characterized by low end-tidal partial pressure of 
carbon dioxide (pCO2), high ventilation equivalents for carbon dioxide (VE/VCO2), 
low oxygen pulse (VO2/HR), and low peak oxygen uptake (peak VO2) [134, 135]. 
These parameters have been included in the ESC/ERS risk assessment algorithm. 
Peak VO2 > 15 ml/min/kg or greater than 65% predicted and a VE/VCO2 slope < 36 
portend a more favorable prognosis and represent goals of targeted therapy [136].
5.1.2 Echocardiography and hemodynamics
Echocardiography is not only a valuable screening tool for detecting the presence 
of pulmonary hypertension, but it plays a role in assessing severity of illness and 
response to treatment. The measurement of pulmonary artery pressure (PAP) by 
echocardiography is not a reliable prognostic indicator, nor does it accurately reflect 
progression or improvement in pulmonary vascular resistance [121, 128]. The 
absence of tricuspid regurgitation and/or poor image quality limits the ability to 
determine systolic PAP by echocardiography in 20–39% of patients [121]. The value 
of echocardiography in assessing severity of illness lies in measurement of chamber 
sizes, assessment of right ventricular (RV) function, and the presence or absence 
of pericardial effusion which is considered a reflection of RV failure. A complete 
echocardiographic assessment in the PAH patient would include description of right 
atrial (RA) and RV dimensions, measurement of tricuspid regurgitant velocity, left 
ventricular (LV) eccentricity index, and RV contractility [137, 138]. RV contractil-
ity can be determined from RV longitudinal systolic strain/strain rate, RV fractional 
area change, Tei index, or tricuspid annular plane systolic excursion (TAPSE) [137, 
139]. Echocardiography with exercise may provide useful information about RV 
function. An increase in estimated PAP by >30 mmHg during exercise indicates 
better RV reserve associated with better long-term outcome and is considered an 
Table 4. 
The World Health Organization (WHO) functional class.
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independent marker of prognosis in PAH [140]. A right atrial area < 18 cm3 with 
no evident pericardial effusion are indicators for favorable prognosis or treatment 
outcome [16]. Additional information about prognosis or treatment effect can be 
gained from right heart catheterization and hemodynamic measurements. As in the 
case of echocardiography, PA pressure is of little value. Cardiac index, RA pressure, 
and mixed venous oxygen saturation have been shown to have the greatest prog-
nostic significance [128, 129]. Goals of therapy that are associated with favorable 
prognosis include CI ≥ 2.5 L/min/m2, RA pressure < 8 mmHg, and SvO2 > 65% [16].
5.1.3 Biomarkers
There are a number of biomarkers of vascular dysfunction, inflammation, 
cardiac function, and tissue hypoxia that have been investigated as a specific 
marker for pulmonary vascular remodeling [141–144]. Of these, brain natriuretic 
peptide (BNP) and NT-proBNP are used in clinical practice and research [145–147]. 
These biomarkers reflect ventricular wall stress, as seen in volume overload and 
ventricular contractile dysfunction, and serve as surrogate indicators of myocar-
dial dysfunction [122, 148]. Either marker is considered an acceptable choice for 
assessing severity of illness. BNP has slightly better correlation with pulmonary 
vascular hemodynamics and is less likely to be affected by renal function, while 
NT-proBNP appears to be a stronger predictor of prognosis [149]. Compared to 
BNP, NT-proBNP is more sensitive to early increases in systolic PAP as measured 
by echocardiography [150]. BNP levels below 50 ng/L or NT-proBNP levels below 
300 ng/L are associated with a more favorable prognosis [16].
5.1.4 Monitoring
Implementation of the prognostic indicators outlined in Figure 2 is variable 
among centers providing expert care for patients with PAH. After a treatment plan is 
established, patients will typically be reevaluated every 3–4 months depending on sta-
bility of their disease. During early phases of treatment or times when therapy targets 
indicate a need to alter the treatment plan, patients are often seen more frequently. It 
is not practical to perform all of the measures listed in Figure 3 at every visit. In the 
outpatient setting, clinicians tend to rely on assessment of symptoms, physical exam 
findings, FC, 6 MW distance, and BNP or NT-proBNP levels to determine severity of 
disease at any given point in time. This information may be supplemented periodi-
cally with echocardiography or cardiopulmonary exercise testing. Right heart cath-
eterization is performed initially at diagnosis and in some centers yearly thereafter or 
in the event condition deteriorates in those patients with high-risk features. In other 
centers repeat hemodynamic measurements are obtained less frequently and typically 
if there is an indication the patient’s condition is progressing.
Once the diagnosis is established and severity of illness is defined, decisions 
about disease-targeted therapy can be made. Available targeted therapies exert 
clinical benefit via the nitric oxide, endothelin, or prostacyclin pathways which 
were discussed earlier in this chapter. There are several options that affect each of 
these pathways. The choice of therapy for any given patient will depend on severity 
of illness and may be further influenced by side effects, safety issues, and in some 
cases economic and social support factors.
5.2 Phosphodiesterase 5 inhibitors
The phosphodiesterase 5 (PDE-5) inhibitors effect smooth muscle relaxation 
and inhibit proliferation and inflammatory mechanisms by augmenting cyclic 
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guanosine monophosphate (cGMP) activity in pulmonary vascular smooth 
muscle. As noted earlier in this chapter, patients with PAH have been shown to 
have deficient nitric oxide synthase activity in the pulmonary vasculature lead-
ing to a deficiency of nitric oxide production [54]. Nitric oxide is produced by the 
pulmonary endothelium and catalyzes the production of cGMP in nearby smooth 
muscle cells. PDE-5 degrades cGMP, thus limiting its effect on smooth muscle cells. 
The phosphodiesterase 5 inhibitors sildenafil and tadalafil block the degradation of 
cGMP, thus permitting beneficial cGMP effects to continue.
5.2.1 Sildenafil
Sildenafil has been shown to improve symptoms, exercise capacity, and hemo-
dynamics in patients with PAH including those with connective tissue disease 
(CTD) [151, 152]. It is available as an oral agent prescribed at 20 mg tid. This drug 
is generally well tolerated with most common side effects including headache, 
flushing, nausea, and nasal congestion, all resulting from vasodilation. The use of 
nitroglycerin is contraindicated in patients taking sildenafil due to a risk of severe 
hypotension when these drugs are used in combination. Safety during human 
pregnancy has not been studied; however no fetal harm has been noted in animal 
studies.
5.2.2 Tadalafil
Tadalafil has also proven to have beneficial effects on symptoms, exercise capac-
ity, hemodynamics, and time to clinical worsening in a large randomized clinical 
trial involving 405 PAH patients including 95 with connective tissue disease [153]. 
Tadalafil’s greatest benefit was realized at a dose of 40 mg daily. The drug is well 
tolerated with side effects and precautions similar to sildenafil.
5.2.3 Vardenafil
Vardenafil is a third agent within the PDE-5 inhibitor class that demonstrated 
significant advantage when comparing 6 MW distance, cardiac index, mean PA 
pressure, and pulmonary vascular resistance in patients treated with vardenafil 
5 mg twice daily or placebo [154]. The long-term effects of vardenafil in PAH have 
not been evaluated, and the drug has not been approved for the treatment of PAH in 
the United States.
5.3 Soluble guanylate cyclase stimulators
While the phosphodiesterase 5 inhibitors promote vasodilation and limit 
proliferation by preventing the degradation of cGMP, the soluble guanylate cyclase 
(sGC) stimulator riociguat interacts directly with guanylate cyclase to stimulate 
production of cGMP [54].
5.3.1 Riociguat
Riociguat is the only member of this family in use to date. Riociguat was 
studied in two randomized clinical trials, one focused on patients with PAH 
(PATENT 1) and included those with CTD [155] and the other patients with 
chronic thromboembolic pulmonary hypertension (CTEPH) [156]. Significant 
improvements were observed in exercise capacity, FC, time to clinical worsen-
ing, and hemodynamics. Subgroup analysis of the PATENT 1 trial specifically 
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evaluating benefit in CTD-PAH revealed improvements in 6 MW, FC, pulmonary 
vascular resistance, and cardiac index [157]. Riociguat is an oral therapy with 
maximum daily use of 2.5 mg tid. Side effects are similar to those seen with the 
PDE-5 inhibitors. In addition, riociguat can induce systemic hypotension and has 
been linked to an increased risk of bleeding. It is teratogenic and contraindicated 
in pregnancy. Females of childbearing age are required to participate in a Risk 
Evaluation and Mitigation Strategy (REMS) program and undergo monthly 
pregnancy testing in addition to practicing careful contraceptive measures. This 
drug should not be used with nitroglycerin or PDE-5 inhibitors due to the risk of 
severe hypotension.
5.4 Endothelin receptor antagonists
Excessive levels of endothelin 1 produced by pulmonary vascular endothelial 
cells have been implicated in the vasoconstriction and cell proliferation seen in PAH 
[57, 158, 159]. Endothelin binds with two G protein-coupled receptors, type A and 
B, located on the smooth muscle cell surface and thereby promotes its physiologic 
effects. Type A receptors mediate vasoconstriction, cell growth, and inflammation, 
while type B receptors mediate opposing effects including vasodilation and natri-
uresis while inhibiting proliferation and inflammation.
5.4.1 Bosentan
Bosentan was the first targeted oral therapy developed to treat PAH and is 
prescribed with a bid dosing schedule. Bosentan has been investigated in patients 
with iPAH, PAH associated with CTD, and Eisenmenger syndrome [160–162]. The 
drug interacts with both type A and B receptors to effect improvements in exercise 
capacity, FC, time to clinical worsening, hemodynamics, and echocardiographic 
variables [163]. About 10% of patients treated with bosentan in clinical trials 
developed reversible elevations in liver transaminases. Monthly monitoring of 
liver function tests is required for patients using bosentan. Other side effects that 
can be seen are fluid retention and anemia. Further, this drug is teratogenic and 
contraindicated during pregnancy. Females of childbearing age who use bosentan 
must enroll in a Risk Evaluation and Mitigation Strategy (REMS) program and are 
required to undergo monthly pregnancy testing. They should be counseled to avoid 
pregnancy with careful contraceptive practices if sexually active. It is important 
to note that hormonal contraceptive effectiveness is reduced by bosentan. It is also 
important to note that cyclosporine and glyburide may increase bosentan levels and 
increase the risk of liver toxicity.
5.4.2 Ambrisentan
Ambrisentan is a selective endothelin type A receptor blocker which is available 
as an oral therapy prescribed for once daily use. This drug has been studied in one 
pilot and two randomized clinical trials demonstrating improvements in symptoms, 
exercise capacity, time to clinical worsening, and hemodynamics in patients with 
iPAH, CTD-PAH, and HIV-associated PAH [164, 165]. The risk of liver function 
abnormalities is minimal, and monthly liver function testing is not required for 
patients using ambrisentan; however its use is not recommended in patients with 
moderate to severe liver dysfunction. Ambrisentan use can be complicated by the 
development of edema and anemia. Like bosentan, ambrisentan is teratogenic and 
contraindicated during pregnancy. All of the precautions relating to use in females 
of childbearing age noted for bosentan are also true for ambrisentan.
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5.4.3 Macitentan
Macitentan is the most recent endothelin 1 antagonist available to PAH patients 
as a once daily oral therapy. Like bosentan, macitentan is a dual endothelin receptor 
blocker. In contrast to bosentan and ambrisentan, the benefits of macitentan were 
realized in a large event-driven investigation involving 742 patients treated for an 
average of 100 weeks [166]. Macitentan significantly reduced time from initiation 
to a composite endpoint of worsening PAH, initiation of intravenous or subcutane-
ous prostanoid therapy, atrial septostomy, lung transplantation, or death. The study 
population included a significant proportion of patients on background therapy 
who also experienced significant benefit. Macitentan is well tolerated and, as with 
other endothelin antagonists, may be associated with fluid retention or anemia. 
Again, this drug is teratogenic and contraindicated during pregnancy. Patients 
using this drug should follow the same risk reduction recommendations as noted 
with bosentan and ambrisentan.
5.5 Prostacyclin analogues
A deficiency of prostacyclin activity characterizes the dysfunction of the third 
major pathway involved in the development of PAH. Prostacyclin is produced by 
the pulmonary endothelium, and its bioactive effects include vasodilation of the 
pulmonary vascular bed, inhibition of platelet aggregation, and cell proliferation 
[167]. A reduction of prostacyclin synthase expression has been recognized in 
pulmonary arteries from patients with PAH and is thought to be the central focus of 
dysfunction in this pathway [55]. The prostacyclin analogues are available as oral, 
inhaled, or systemically administered disease-targeted therapies.
5.5.1 Epoprostenol
Epoprostenol is available for use as a continuous intravenous (IV) infusion. 
Epoprostenol has a short half-life of 3–5 min. The original formulation was unstable 
at room temperature after about 8 h and required considerable effort to maintain 
at cooler temperatures. A newer formulation of the drug is now available that has 
extended room temperature stability. Treatment is initiated at a dose of 2–4 ng/
kg/min and titrated upward to reach clinical therapy targets. Patients experience 
tachyphylaxis with the continuous infusion, therefore requiring intermittent dose 
escalation over time. The maximum beneficial dose of epoprostenol is typically 
40 ng/kg/min, although titration may go beyond this point. Epoprostenol has been 
shown to improve symptoms, exercise capacity, and hemodynamics in FC 3 and 4 
patients with iPAH and SSc-PAH [168–170]. Side effects with epoprostenol can be 
pronounced and may include jaw pain, nausea, diarrhea, flushing, and headache. 
There is a risk of catheter-related complications including infection and thrombo-
sis. Epoprostenol can cause hypotension when used with other antihypertensives 
and may increase risk of bleeding when used in patients taking anticoagulants or 
antiplatelet agents. Epoprostenol has been used during pregnancy without evidence 
of fetal harm to date. Given the short half-life of epoprostenol, an infusion of this 
drug should not be discontinued abruptly due to the risk of rebound pulmonary 
vasoconstriction and death.
5.5.2 Treprostinil
Treprostinil is an analogue of epoprostenol available in systemic, inhaled, 
and oral formulations. The systemically infused form of treprostinil is stable at 
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room temperature, has a half-life of 3–4 h, and can be administered by continuous 
subcutaneous (SC) or IV infusions. Dosing typically begins with 1–2 ng/kg/min 
with gradual dose escalation to achieve clinical target goals. Side effects are similar 
to epoprostenol. Additionally those patients using the subcutaneous formulation 
may experience significant infusion site pain. Several topical analgesic prepara-
tions are available that can successfully control local infusion site pain. As is the 
case with epoprostenol, patients develop tachyphylaxis requiring dose escalation 
to maintain clinical benefit. The usual effective dose is 20–80 ng/kg/min, although 
dosing can extend well beyond this range. Treprostinil was first studied in its 
continuous SC formulation. A randomized clinical trial of 470 patients treated with 
SC treprostinil, including 17% CTD patients, revealed improvements in exercise 
tolerance and hemodynamics [171, 172]. Dose titration was limited by side effects, 
including infusion site pain, and as such benefits were noted in those patients 
achieving higher doses >13.8 ng/kg/min. Later treprostinil was approved for use as a 
continuous IV infusion. Treprostinil can be administered in an inhaled formulation 
with a specialized nebulizer four times daily. This formulation is very well toler-
ated with most commonly reported effects including mouth soreness, cough, and 
headache. Tachyphylaxis does not develop due to intermittent dosing. Some patients 
may notice recurrence of PAH symptoms as effect wanes between treatments. In 
a randomized clinical trial of inhaled treprostinil added to background therapy 
with bosentan or sildenafil, there were improvements in 6 MW, NT-proBNP levels, 
and quality of life measures [173]. More recently, treprostinil has been offered in 
an oral formulation that is taken by either bid or tid scheduled dosing. Although 
intermittent dosing is employed in the treatment of patients with oral treprostinil, 
dose escalation over time helps achieve and maintain clinical target goals. The use of 
oral treprostinil can be complicated by significant gastrointestinal side effects, such 
as nausea, anorexia, and diarrhea. In a randomized clinical trial of treatment-naïve 
PAH patients, oral treprostinil use was associated with improvement in 6 MW dis-
tance [174]. Treprostinil can cause hypotension when used with other antihyperten-
sives and may increase risk of bleeding when used in patients taking anticoagulants 
or antiplatelet agents. Parenteral and inhaled treprostinil safety during pregnancy 
has not been studied in humans but did not lead to fetal harm in animals, and as 
such they have Category B designations. Oral treprostinil has been associated with 
adverse fetal effects in animal studies and is designated Category C. Continuous 
IV therapy carries a risk of catheter-related complications including infection and 
thrombosis. Oral treprostinil use is contraindicated in patients with Child-Pugh 
Class 3 hepatic impairment. Treprostinil should not be discontinued abruptly due to 
the risk of rebound pulmonary vasoconstriction and death.
5.5.3 Iloprost
Iloprost is a stable analogue of prostacyclin that is also available in IV, inhaled, 
or oral formulations. Oral iloprost has not been evaluated for use; however, both 
the IV and inhaled forms have been used in Europe, and the inhaled form has been 
approved for use in the United States. The inhaled formulation is administered 
with a specifically designed handheld and portable nebulizer device. This form of 
iloprost is used by nebulization 6–9 times a day at a dose of 2.5–5 ug/inhalation. The 
effect lasts from 30 to 90 min. The intermittent dosing eliminates the development 
of tachyphylaxis. Improvements in symptoms, exercise capacity, and pulmonary 
vascular resistance were observed in a clinical trial in which iloprost was compared 
with placebo in patients with PAH and CTEPH [175]. The effect of IV iloprost 
was noted to be similar to epoprostenol in a small group of patients with PAH and 
CTEPH [176]. The inhaled drug is well tolerated with most frequent side effects 
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being cough, flushing, and jaw pain. Inhaled iloprost can cause hypotension and 
should be avoided or used cautiously in patients with relative hypotension.
5.6 Prostacyclin receptor agonist
The development of the prostacyclin receptor agonist class of disease-targeted 
therapies represents a new approach to treating PAH. Although the prostacyclin 
receptor agonism of this new class is similar to that of prostacyclins, the receptor 
interaction is selective for the IP receptor. The established prostanoid receptors 
in the human pulmonary artery are the IP, EP3, and TP receptors. The IP receptor 
mediates vasodilation and inhibits proliferation, while the EP3 and TP receptors 
may promote vasoconstriction and cell proliferation [177–179].
5.6.1 Selexipag
Selexipag is a selective IP receptor agonist that is structurally distinct from 
prostacyclin with an active metabolite that is 37-fold more potent. Selexipag is 
prescribed for oral BID dosing beginning with 200 mcg bid and titrating to a maxi-
mal dose of up to 1600 mcg bid. The target treatment dose for individual patients 
is determined by the development of side effects limiting further dose escalation. 
Selexipag reduced the risk of reaching a composite morbidity and mortality (wors-
ening PAH resulting in need for atrial septostomy or lung transplantation, initiation 
of parenteral prostanoid therapy or chronic oxygen therapy, hospitalization for 
PAH, other indication of disease progression, or death) by 40% in a large placebo-
controlled, event-driven trial including 1156 patients [180, 181]. At baseline, 80% 
of patients were being treated with stable doses of an endothelin blocker, a PDE-5 
inhibitor, or both. A subgroup analysis of 334 patients with connective tissue 
disease-associated PAH (170 SSc, 82 systemic lupus, 82 mixed or other) revealed 
a similar 41% reduction in risk of the composite morbidity and mortality events 
[182]. Further the treatment effect was consistent regardless of background PAH 
treatment or connective tissue disease subtype. Commonly reported side effects 
include headache, nausea, diarrhea, flushing, myalgia, and arthralgia.
5.7 Combination therapy
Despite observations from clinical trials that individual therapeutic agents 
can improve exercise capacity, time to clinical worsening, and hemodynamics, 
pulmonary arterial hypertension remains a progressive disease that is difficult 
to control. The progressive nature of this disease process in patients treated with 
monotherapy has fostered the practice of combining agents to limit progression. 
One approach has been the sequential addition of agents affecting the three known 
pathophysiologic pathways. In this approach an agent affecting one of the path-
ways is chosen to begin monotherapy and if clinical response is inadequate, one or 
more agents affecting the other pathways are added until desired clinical benefit is 
achieved. Upfront combination therapy has become a more contemporary approach 
to managing pulmonary arterial hypertension. This approach to treating PAH 
was conceived from experience with the treatment of other disease states, such as 
cancer or congestive heart failure, with agents affecting multiple mechanisms of 
disease upfront. The upfront combination approach gained momentum with the 
AMBITION trial which demonstrated a 50% reduction in composite morbidity/
mortality events in patients treated with an upfront combination of tadalafil and 
ambrisentan compared to either agent as monotherapy [183]. This benefit was also 
recognized in a subgroup analysis of patients with CTD-PAH and SSc-PAH [184]. 
New Insights into Systemic Sclerosis
24
Hemodynamics, RV structure and function, and overall functional status were sig-
nificantly improved in SSc-PAH patient treated with the upfront combination [185]. 
Investigations of several newer treatments for PAH, such as riociguat, macitentan, 
and selexipag, have included significant proportions of patients on background 
therapies and have demonstrated added improvements in exercise capacity, func-
tional class, and time to clinical worsening [155, 166, 181]. These studies have fueled 
the impetus to include recommendations for combination therapy in contemporary 
treatment guidelines [16, 186].
5.8 Nonmedical treatment options
Medical therapy can improve activity tolerance, hemodynamics, and quality 
of life and can even improve survival prognosis; however, in some cases PAH will 
progress even with aggressive medical therapy. Nonmedical options may include 
balloon atrial septostomy and/or lung transplantation. Atrial septostomy may be 
beneficial in FC 4 patients with right heart failure or severe syncopal symptoms 
who are progressing on maximal medical therapy [187]. Atrial septostomy is also 
a consideration as a bridge to lung transplantation when medical therapy fails. An 
interatrial right-to-left shunt may decompress the right heart chambers and ulti-
mately improve oxygen transport despite an observed oxyhemoglobin desaturation 
[188]. Atrial septostomy is not recommended in end-stage patients with mean RAP 
>20 mmHg and a resting room air saturation below 85% [187, 188]. Lung transplan-
tation is also an option for patients with end-stage SSc-PAH failing medical therapy. 
In some centers, patients with SSc-PAH may not be offered lung transplantation due 
to the risk of aspiration pneumonia related to esophageal disease. However, stud-
ies have shown that survival after lung transplantation is similar in patients with 
SSc-PAH and other transplant indications [189]. There has been increasing interest 
in stem cell therapy as a treatment option for PAH. Although animal models have 
shown some promise, stem cell therapy is not currently a viable option for treat-
ment of human PAH [190].
5.9 Treatment algorithm
The poor survival prognosis associated with SSc-PAH and the availability of mul-
tiple disease-targeted treatment options have fostered the development of algorithms 
to guide the treatment decision process. Both the American College of Chest Physicians 
[186] and the Joint Task Force for the Diagnosis and Treatment of Pulmonary 
Hypertension of the ESC/ERS [16] have published guidelines to aid clinicians in the 
treatment of patients with PAH.
5.10 Supportive measures
In addition to a careful risk assessment, choice of appropriate disease-targeted 
agent, and close monitoring of treatment effect, there are severe supportive 
measures that apply in the management of the patient with SSc-PAH. Patients are 
not restricted from physical activity. Physical activity and supervised rehabilita-
tion have been shown to improve exercise tolerance, reduce fatigue, and improve 
quality of life [191, 192]. The ESC/ERS Guidelines suggest that patients who are 
stable clinically should consider participation in a rehabilitation program at a 
center experienced with the management of PAH if possible [16]. Patients with 
SSc-PAH should be vaccinated against influenza and pneumococcal pneumonia. 
Pregnancy in patients with PAH is associated with a high mortality risk and should 
be avoided. If patients with PAH become pregnant, the high risk of complications 
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and pregnancy termination should be discussed. Some PAH treatments cause fetal 
harm, and patients are required to undergo monthly pregnancy monitoring when 
using such therapies. Riociguat and the endothelin antagonists are teratogenic. 
Patients using these targeted therapies should be carefully counseled about the 
risk of fetal harm and instructed to use at least two barrier methods of contracep-
tion while using these agents. In the event patients do become pregnant, they may 
continue PAH therapies that are not considered fetal toxic, such as the prostanoids, 
plan an elective delivery, and work closely with a high-risk obstetrical team and 
experienced pulmonary hypertension specialist throughout the pregnancy [193]. 
Patients with PAH are often overwhelmed by the physical limitations, financial 
burden, and social impact associated with PAH [194]. Screening for depression 
is helpful in identifying patients who could benefit from referral to appropriate 
services in the community where help is available to ease the psychosocial burden 
of this disease. Genetic counseling may be appropriate for select patients [195]. It 
is often helpful for the affected patient and at-risk family members to understand 
their mutation status in order to plan for the future. Genetic testing and counseling 
should involve a multidisciplinary team including pulmonary hypertension special-
ists, genetic counselors, geneticists, psychologists, and nurses. Elective surgery is 
not contraindicated but does carry an increased risk to the PAH patient. Patients 
with significantly impaired RV function are at highest risk and should undergo 
careful preoperative assessment [196–198]. Epidural anesthesia may be better toler-
ated [199]. Patients using oral therapies may require transition to an intravenous or 
inhaled form of therapy until able to take oral medications postoperatively.
6. Conclusions
Pulmonary arterial hypertension is a leading cause of death in patients with 
systemic sclerosis. While the pathogenesis of PAH in the patient with systemic 
sclerosis bears resemblance to that of idiopathic PAH, there are distinct differences 
in genetic predisposition, role of inflammation and autoantibodies, and pathologic 
manifestations of disease. Early detection is essential in preventing early demise 
from SSc-PAH. Several algorithms have been suggested for screening SSc patients 
for PAH. In general, it is recommended that annual screening with biomarkers, 
PFTs, and echocardiography be considered in any patient with systemic sclerosis, 
even if they are asymptomatic. There are a number of medical therapies available 
which have demonstrated benefit in SSc-PAH, as well as iPAH. The importance of 
regular monitoring and repeat risk assessment cannot be underemphasized. Lung 
transplantation may be an option for those patients who progress on maximal medi-
cal therapy. While the prognosis for SSc-PAH has certainly improved over the past 
two decades, continued research into the mechanisms of disease and development 
of new treatments will ensure further improvements in quality of life and survival 
in the future.
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